Business
Ordinary Annual General Meeting of Formycon AG Approves all Proposed Resolutions by Large Majorities
Management provides detailed report on financial year 2024 and provides outlook for 2025 Supervisory Board expands to six members; Klaus Rhrig re-elected Dr. Graham Keith Dixon elected as a new member of the Supervisory Board PLANEGG-MARTINSRIE...
About this update from Formycon Ag
[{"type":"table","headerItems":[],"items":[{"val":[{"val":[{"type":"list","items":[{"val":[{"type":"text","content":"Management provides detailed report on financial year 2024 and provides outlook for 2025","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Supervisory Board expands to six members; Klaus Rhrig re-elected","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Graham Keith Dixon elected as a new member of the Supervisory Board","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":223,"olType":false},{"type":"text","content":"PLANEGG-MARTINSRIED, Germany - June 18, 2025 (NEWMEDIAWIRE) - Formycon AG (FSE: FYB, "Formycon") held its Annual General Meeting on 18 June 2025 as an in-person event in Munich. In its presentation, the Management Board provided shareholders with a detailed report on the company's development and answered all questions in the general debate.","length":357,"tagName":"p"},{"type":"text","content":"In its report to the Annual General Meeting, the Management Board highlighted Formycon's strong operational performance in the 2024 fiscal year and provided a detailed outlook for the ongoing year 2025. The company has successfully evolved in recent years from a purely development-focused organization into a commercially oriented biosimilar company with a steadily expanding and maturing product portfolio. Increasing revenues from global licensing and commercialization partnerships now provide a robust foundation for implementing the company's growth strategy. The Management Board reaffirmed its commitment to maintaining this positive momentum, unlocking new market opportunities, and further expanding Formycon's international presence.","length":756,"tagName":"p"},{"type":"text","content":"The represented shareholders followed the proposals of the Management Board and Supervisory Board and approved all of the Executive Board's proposed resolution resolutions with large majorities. Both the members of the Management Board and the Supervisory Board were given a formal approval of their actions with majorities of over 97 per cent in each case.","length":361,"tagName":"p"},{"type":"text","content":"The resolution to expand the Supervisory Board from five to six members was passed to meet the growing requirements for the Board following the Company's listi...